NEWARK, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today reported its financial and operating results for the three months ended September 30, 2015.
“We continue to advance our HuCNS-SC® human neural stem cells platform through Phase II clinical programs in both spinal cord injury and age-related macular degeneration,” reported StemCells CEO Martin McGlynn. “Later this month, we look forward to providing an update on the progress of the Phase II Pathway study, as well as a summary of interim data from Cohort I of the study. Cohort I is an open-label six-patient cohort designed to assess the safety and clinical effect of three ascending doses of cells into the cervical region of the spinal cord.”
Help employers find you! Check out all the jobs and post your resume.
